Praemium Ltd (ASX: PPS), the investment administration and platform provider, has announced that gross inflows of $760 million over the last quarter have driven its funds under administration (FUA) to $8.3 billion as at 30 June 2018.
This ranks in the top 5 best quarters for Praemium in terms of gross inflows both for its Australian business (third highest on record) and its international business (fourth highest on record).
It also means that Praemium had a record $3 billion gross inflow in FY 2018, 50% higher than the gross inflows it had last year.
No sign of stopping
Praemium’s FUA growth has been driven by a number of factors including:
- New client wins with Morgan Stanley Wealth Management, CMC Markets and JB Were all signing up with Praemium over the last quarter
- Tailwinds in the superannuation and pension fund industries
A look at the graph below which depicts Praemium’s FUA since 2014 shows a relentless push upwards and there are no signs of that graph flattening any time soon, particularly when you consider that superannuation guarantee rates are set to increase over the next couple of years.
Interestingly enough as well, the international business as a percentage of Praemium’s overall portfolio has increased over time and that could be an area of growth in the future.
Source: Praemium ASX announcement
That growth has not gone unnoticed as all three companies have seen their share prices run up 109%, 76% and 36% respectively over the last year.
These companies are priced for growth and so funds under administration will need to keep increasing rapidly to justify their share price.
For now, with industry tailwinds on their back, that looks likely to continue.
Praemium is not the only small cap that has performed really well recently. This FREE REPORT identifies a high margin small cap that has been identified by our team of experts as their number 1 medical technology pick.
The ASX small cap up 285% with no sign of stopping...
One Australian company has developed a state of the art device that's revolutionizing hospitals all over the world. Even better, this device is so profitable that the company rakes in 90% margins. That's a lot of cash. So no wonder the stock's up 285% since 2008 – with no signs of stopping...
To discover the name and code, simply click the link below. You'll discover our expert's #1 medical technology pick... and you can decide for yourself whether to get invested today.
Click here to claim your free report.
You can find Kevin on Twitter @KevinGandiya.
The Motley Fool Australia has recommended Onevue Holdings Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.